Fulcrum Therapeutics (FULC)
(Delayed Data from NSDQ)
$7.32 USD
+0.02 (0.27%)
Updated Sep 17, 2025 04:00 PM ET
After-Market: $7.32 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
FULC 7.32 +0.02(0.27%)
Will FULC be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for FULC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FULC
Fulcrum Therapeutics (FULC) Upgraded to Buy: Here's Why
New Strong Buy Stocks for November 12th
FULC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Fulcrum Before Q3 Earnings: How Should Investors Play the Stock?
Fulcrum Stock Tanks 58% in a Month: Buying Opportunity or Risky Bet?
Pacira's Exparel Receives Permanent New Product-Specific J-Code
Other News for FULC
Is FULC ready to move higher? Crossed Above 50 Day Moving Average shows up after climbing 3.25%
20 Day Moving Average Support appears for FULC after 1.0% move
Fulcrum Therapeutics (FULC) Receives a Sell from Bank of America Securities
Is FULC signaling a buying opportunity? 20 Day Moving Average Support shows up after advancing 0.14%
Is FULC likely to continue lower? 50 Day Moving Average Resistance shows up after a flat session